New combo therapy targets hard-to-treat breast cancer
NCT ID NCT07244874
First seen Nov 24, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests whether combining two drugs (Sacituzumab Tirumotecan and Toripalimab) can shrink or control advanced triple-negative breast cancer that has a specific protein (PD-L1). About 41 women with this type of breast cancer will receive the treatment. The goal is to see how well the combination works and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.